EGFR and non-small cell lung carcinoma: Overall, the majority of current clinical evidence demonstrated that EGFR and ALK wild-type advanced-stage NSCLC patients with high PD-L1-expressing tumors benefited the most from anti-PD-(L)1 ICIs, despite quantitative variations between the currently available PD-L1 immunohistochemistry (IHC) assays [5,11].